Simnotrelvir as a potential treatment for COVID-19

Matthew W McCarthy,Matthew W. McCarthy

DOI: https://doi.org/10.1080/14656566.2024.2323597

2024-02-28

Expert Opinion on Pharmacotherapy

Abstract:Introduction Simnotrelvir is a selective 3-chymotrypsin-like oral protease inhibitor with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

pharmacology & pharmacy